


Seeking Novel Drugs to Treat Autoimmune Diseases

Asahi Kasei Pharma, a global pharmaceutical company, is seeking promising **novel drugs for the treatment of a wide range of autoimmune diseases**. Specifically, the team is interested in drug candidates that **target autoimmune disease pathways**, including those that have potential to be applied to a variety of diseases.



Approaches of Interest:

- Asahi Kasei Pharma is open to different modalities including small molecules, peptides, antibodies, proteins and nucleotides
- Opportunities where the **drug candidate has already been identified** are of highest interest
- Data or theories that indicate the drug candidate is superior to existing drugs/therapies is desirable

Out of Scope:

- Drugs that manage the symptoms of autoimmune diseases
- Opportunities related to cell therapy, probiotics, gene editing and AAV therapy, diagnostic products and medical devices
- Drug screening libraries and drug repurposing
- Novel NSAIDs and JAKi are out of scope, however, JAKi that have dual inhibition, including the JAK/BTK inhibitor, remain of interest

Developmental Stages of Interest:

- Opportunities from early discovery phase to late preclinical stage are of interest
- Drug candidate efficacy should at least be confirmed in an *in vitro* study that reflects the treatment concept
- Confirmation of the drug candidate's effectiveness in an *in vivo* study using an animal model is desirable
- Research and development programs after target validation can be applicable


Submission Information

Submission of one page, 200-300 word briefs are encouraged, along with any optional supplementary information e.g. relevant publications. Submissions should include information regarding unpublished/filed/published patents, if any. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets and research collaborations.

Opportunities sought

-  Technologies
-  Academics and expertise
-  Centres of excellence
-  Research projects
-  Spinout companies
-  Biotech assets

Submissions

Please submit relevant, non-confidential opportunities online [here](#)

Deadline: **26th February 2024 - 11:59 pm GMT**

Have any questions?

Contact our team at discover@in-part.co.uk